Edwards Lifesciences Co. (NYSE:EW) Receives Average Recommendation of “Buy” from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have earned an average rating of “Buy” from the twenty-one research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $86.09.

Several equities analysts recently commented on EW shares. Jefferies Financial Group upped their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 24th. SVB Leerink upped their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 12th. Cowen upped their target price on Edwards Lifesciences from $85.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Raymond James upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Credit Suisse Group upped their target price on Edwards Lifesciences from $92.00 to $97.00 and gave the company an “outperform” rating in a research note on Thursday.

In related news, VP Larry L. Wood sold 10,698 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $78.40, for a total value of $838,723.20. Following the transaction, the vice president now owns 374,181 shares in the company, valued at $29,335,790.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 2,249 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $78.24, for a total value of $175,961.76. Following the completion of the transaction, the vice president now owns 26,746 shares in the company, valued at approximately $2,092,607.04. The disclosure for this sale can be found here. Insiders sold 429,773 shares of company stock valued at $34,576,732 in the last ninety days. Company insiders own 1.48% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Edwards Lifesciences by 218.6% in the second quarter. BlackRock Inc. now owns 59,443,975 shares of the medical research company’s stock worth $4,108,172,000 after acquiring an additional 40,784,244 shares in the last quarter. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 196.4% during the second quarter. Vanguard Group Inc. now owns 49,428,510 shares of the medical research company’s stock valued at $3,416,005,000 after buying an additional 32,751,525 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 210.6% during the second quarter. Bank of New York Mellon Corp now owns 20,345,153 shares of the medical research company’s stock valued at $1,406,055,000 after buying an additional 13,794,673 shares in the last quarter. FMR LLC raised its stake in Edwards Lifesciences by 97.2% during the second quarter. FMR LLC now owns 12,366,132 shares of the medical research company’s stock valued at $854,623,000 after buying an additional 6,095,867 shares in the last quarter. Finally, State Street Corp raised its stake in Edwards Lifesciences by 0.9% during the first quarter. State Street Corp now owns 8,998,907 shares of the medical research company’s stock valued at $1,697,374,000 after buying an additional 81,976 shares in the last quarter. Institutional investors and hedge funds own 79.70% of the company’s stock.

Shares of NYSE EW traded down $1.97 during trading on Monday, reaching $78.44. The company had a trading volume of 72,025 shares, compared to its average volume of 3,657,628. Edwards Lifesciences has a twelve month low of $51.51 and a twelve month high of $87.79. The stock has a market capitalization of $49.99 billion, a PE ratio of 67.02, a price-to-earnings-growth ratio of 2.86 and a beta of 0.90. The stock has a 50-day moving average price of $81.88 and a two-hundred day moving average price of $85.24. The company has a current ratio of 3.08, a quick ratio of 2.24 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.45 by $0.06. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 17.21%. On average, sell-side analysts predict that Edwards Lifesciences will post 1.86 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More: What Are Treasury Bonds?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.